KTOV - Kitov Pharma Ltd

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.3300
-0.1100 (-7.64%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.4400
Open1.4100
Bid1.42 x 1000
Ask1.44 x 1000
Day's Range1.3100 - 1.4400
52 Week Range0.5600 - 3.8100
Volume1,957,237
Avg. Volume1,746,706
Market Cap20.054M
Beta (3Y Monthly)3.11
PE Ratio (TTM)N/A
EPS (TTM)-0.98
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Kitov Closes $6 Million Registered Direct Offering

    TEL-AVIV, Israel, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced the closing of its previously announced registered direct offering of 3,428,572 American Depositary Shares (ADS) at a purchase price of $1.75 per ADS, for gross proceeds of $6 million. Kitov also issued unregistered warrants to purchase up to 2,571,430 ADSs. The ADSs described above were offered pursuant to a shelf registration statement on Form F-3 (File No. 333-215037), which was declared effective by the United States Securities and Exchange Commission (the “SEC”) on December 14, 2016.

  • ACCESSWIRE3 days ago

    Small Caps Soaring Off of Bottoms

    HENDERSON, NV / ACCESSWIRE / January 18, 2019 / Small cap stocks give investors the opportunity at huge gains relatively quickly. Due to their low price and volatility, it is a space where investors can ...

  • Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
    Zacks3 days ago

    Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY

    Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.

  • Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings
    Zacks4 days ago

    Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings

    Shares of Kitov Pharma (KTOV) soar about 169% as the company's anti-cancer candidate, NT219 shows positive results.

  • GlobeNewswire5 days ago

    Kitov Announces Pricing of $6 Million Registered Direct Offering

    TEL-AVIV, Israel , Jan. 16, 2019 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors providing for the issuance of 3,428,572 American Depositary Shares (ADS) at a purchase price of $1.75 per ADS in a registered direct offering. Kitov will also issue unregistered warrants to purchase up to 2,571,430 ADSs. The ADSs described above were offered pursuant to a shelf registration statement on Form F-3 (File No. 333-215037), which was declared effective by the United States Securities and Exchange Commission (the “SEC”) on December 14, 2016.

  • ACCESSWIRE5 days ago

    4 Healthcare Stocks Seeing Gains On Wednesday (1/16/19)

    CORAL GABLES, FL / ACCESSWIRE / January 16, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Microbot Medical Inc (MBOT), Kitov Pharma Ltd (KTOV), and Teladoc Health Inc (TDOC) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.

  • Kitov Pharmaceuticals News: KTOV Stock Up on Anti-Cancer Drug Findings
    InvestorPlace5 days ago

    Kitov Pharmaceuticals News: KTOV Stock Up on Anti-Cancer Drug Findings

    In the latest Kitov Pharmaceuticals news (NASDAQ:KTOV), the company's stock was skyrocketing on Monday as one of its anti-cancer drugs has yielded encouraging results. Source: Images Money via Flickr (Modified) The Israel-based company announced today the new findings from its NT219 treatment to battle cancer, which it has been studying alongside researchers from the Hebrew University of Jerusalem. The treatment reportedly has high affinity and selective binding to its target proteins. The drug's development is being led by Hadas Reuveni, who is the Chief Technology Officer at Kitov's subsidiary TyrNovo Ltd., as well as Dr. Galia Blum and Dr. Ofra Moshel from the Hebrew University. This team managed to showcase how the NT219 binds directly to Insulin Receptor Substrates (IRS) 1/2 and also to the Signal Transducer and Activator of Transcription 3 (STAT3). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Both of these are known modulators that help to propel tumor survival, metastasis and resistance to drugs. New data shows that NT219 only needs to be exposed to cancerous cells for a short period of time to trigger irreversible shutdown of these pathways, which ultimately leads to a long-term anti-cancer effect. "We are excited about the new data which demonstrate NT219's unique mechanism of action. NT219, a new and promising concept in cancer therapy, is designed to prevent, reverse, and delay resistance to anti-cancer drugs," said Kitov CEO, Isaac Israel. KTOV stock is soaring a whopping 124.7% on Tuesday following the anti-cancer drug findings from the company. ### More From InvestorPlace * Morgan Stanley: 7 Risky Stocks to Sell Now * 10 Stocks You Can Set and Forget (Even In This Market) * The 7 Best Stocks in the Entrepreneur Index Compare Brokers The post Kitov Pharmaceuticals News: KTOV Stock Up on Anti-Cancer Drug Findings appeared first on InvestorPlace.

  • GlobeNewswire6 days ago

    New Data on Kitov’s NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect

    Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced new findings from its ongoing collaboration with researchers from the Hebrew University  of Jerusalem. The data reveal NT219’s high affinity and selective binding to its target proteins. Hadas Reuveni, Ph.D., Chief Technology Officer at Kitov’s subsidiary, TyrNovo Ltd., in collaboration with Dr. Galia Blum and Dr. Ofra Moshel from the Hebrew University demonstrated that NT219 binds directly to Insulin Receptor Substrates (IRS) 1/2 and to the Signal Transducer and Activator of Transcription 3 (STAT3), both known modulators of tumor survival, metastasis and drug resistance.

  • ACCESSWIRE14 days ago

    4 Healthcare Stocks Making Moves On Monday (1/7/19)

    CORAL GABLES, FL / ACCESSWIRE / January 7, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Given that the world's population is consistently increasing, and resources are diminishing, access to healthcare presents a dire need for consumers on a global scale. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare.

  • ACCESSWIRE18 days ago

    4 Healthcare Stocks Gaining Speed on Thursday (1/3/19)

    CORAL GABLES, FL / ACCESSWIRE / January 3, 2019 / The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the ...

  • GlobeNewswire18 days ago

    Kitov Signs Marketing and Distribution Agreement for its Lead Product Consensi™ in the U.S. with Coeptis Pharmaceuticals

    Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced it has signed an exclusive marketing and distribution agreement with Coeptis Pharmaceuticals for the U.S. market. Coeptis will commercialize Kitov’s combination drug, Consensi™, intended to simultaneously treat osteoarthritis pain and hypertension.

  • ACCESSWIRE6 months ago

    Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks

    Stock Research Monitor: KTOV, LOXO, and MDGL LONDON, UK / ACCESSWIRE / July 17, 2018/ If you want a free Stock Review on MRTX sign up now at www.wallstequities.com/registration . Today, WallStEquities.com ...

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Stocks to Watch: Kitov Pharma and Clearside Biomedical

    NEW YORK, NY / ACCESSWIRE / June 1, 2018 / It was FDA news that sent shares of Kitov Pharma blasting off on Thursday. Shares of Clearside Biomedical sunk despite positive topline results being announced ...

  • ACCESSWIRE8 months ago

    Wired News – Kitov Pharma Signs Consensi(TM) Commercialization Deal with Changshan Pharma in China

    LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Kitov Pharma Ltd (NASDAQ: KTOV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KTOV as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it has inked a definitive license and commercialization deal with China-based Hebei Changshan Biochemical Pharmaceutical Co., Ltd ("Changshan"), granting the latter exclusive rights to import, manufacture, and distribute the Company's lead drug candidate, Consensi™, in China.